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Abstract: In the last two decades, the rapid transformation in information and 
communication technologies together with the adoption of more liberal 
structures governing trade as well as the modularisation of production and 
services has resulted in the proliferation of small born-global bio-tech firms. 
The firms have an international flair and they rapidly globalise their operations. 
Their strategic intent is to develop unique innovative capabilities through 
networking. In science-based industries such as the biotechnology sector the 
ability to innovate can only occur if a firm is able to both generate and integrate 
knowledge from inside and outside its boundaries. In that respect, this article 
employs a multi-case approach to construct a frame of reference for developing 
innovative capabilities that complement firm-based competences. The main 
focus is on small born-global bio-tech firms in the East Midlands region of the 
UK. The newly developed framework is invaluable to researchers, small  
born-global bio-tech and large bio-pharmaceutical firms. More so, it 
contributes to the concepts of dynamic capabilities and networking. 
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1 Introduction 
Born-global bio-tech firms are entrepreneurial enterprises which develop complex 
international resource configurations (Karra et al., 2008). Scholars universally agree that 
when a firm ventures beyond its immediate vicinity, it is exposed to unique resource 
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combinations (Schumpeter, 1950; Oviatt and McDougall, 1994; Cooke, 2001;  
Owen-Smith and Powell, 2004; Johnson and Vahlne, 2009). Born-global  
bio-tech firms exhibit characteristics of traditional entrepreneurial firms. For  
example, they are proactive and, innovative and they take risks but in an  
exceedingly complex fashion involving significant degrees of uncertainty synonymous  
with global markets (Burns, 2012). As we strive to understand how these new  
types of international ventures complement their firm-based competences fresh  
and more nuanced theories are needed. From that perspective, the article proposes  
a theoretical framework for born-global bio-tech firms illustrating the complex  
processes and mechanisms in their knowledge supply-chain. Empirical evidence  
from multiple cases of bio-tech firms, in the East Midlands region of the UK,  
is used to construct a new model of ‘knowledge and innovative capability  
development’. 
The model is anchored on the ideas of Freeman et al. (2010). An understanding of 
how born-global bio-tech firms view their social world helps us to interpret and 
comprehend the meanings they attach to their lived world (Pittaway, 2000; Saunders  
et al., 2007). 
1.1 A definition of born-global bio-tech firms 
Born-globals are defined in a number of different ways. For example, Oviatt and 
McDougall (1994) define them as international ventures that seek to derive competitive 
advantage from the use of resources and the sale of outputs in multiple countries. Other 
scholars (see Knight and Cavusgil, 1996; Knight, 2001) use a variety of measures as 
criteria for defining these international ventures such as: the vision and strategy to 
become global, time of internationalisation and overseas sales volumes. Considering  
the different labels used to define born-globals a distinguishing feature in all  
their definitions is that, they adopt a global strategy evidenced by their structural  
dimension which encompasses various actors in multiple countries (Oviatt  
and McDougall, 1994). Regardless, of this distinctive feature there still is no  
universal agreement to a single definition of born-globals. In all the confusion  
and misconceptions regarding the definition of born-global firms, the author is of the  
view that researchers should base their definitions on observable traits. Particularly,  
behaviours that are embedded in the design of the ventures should form the  
basis of how we define them. For example, they should be based on three prominent  
multi-dimensional constructs of social capital identified in the literature as structural,  
relational and cognitive dimensions. Structural dimension is related to global  
network ties and their overall configuration (Burt, 2002; Ahuja, 2000). Relational  
dimension focuses on trust, trustworthiness, norms and obligations in a global network  
(Fukuyama, 1995; Putnam, 1993). Cognitive dimension refers to those resources 
providing ‘shared representations, interpretations, and systems of meaning among 
parties’ [Nahapiet and Ghoshal, (1998), p.244]. From that perspective, it suffices to 
define born-globals as small bio-tech firms which have an international flair and rapidly  
globalise their operations without any preceding long-term domestic or 
internationalisation period. 
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2 Theoretical background 
Scholarship on the internationalisation of small firms is littered with various models 
aimed at explaining their internationalisation processes. From early on Johnson and 
Vahlne (1977) developed the inspirational Uppsala internationalisation model (U-model) 
and it became a widely used model in business management. The model was based on the 
assumption that an enterprise develops in foreign markets by adopting a process which 
evolves incrementally in stages ‘progressing like rings in the water’ Bhowmick (2004, 
p.760). Put in a different way, the enterprise passes from one stage to another as it 
acquires more and more international experience as well as deepening its resource 
commitments. Other management scholars (e.g., Rogers, 1962) have developed the 
innovation diffusion model (I-model) which focuses on internationalisation as innovation 
for the firms. These two models (U and I) became the bedrock of stages theory that 
explained the incremental internationalisation process of small firms. According to 
Andersen (1993, p.212) ‘both the U and I models can be properly regarded as 
behaviourally oriented’. Arguably, the gradual process of internationalisation, as denoted 
on the U and I models, can be seen as a risk-averse strategy adopted by firms as an entry 
mode into foreign markets. Moving forward in 1997, Teece et al. proposed the dynamic 
capabilities theory, they defined the theory as “the ability to integrate, build, and 
reconfigure internal and external competences to address rapidly-changing 
environments”. 
Figure 1 A model of rapid knowledge development: the smaller born-global firm 
 
 
Source: Freeman et al. (2010, p.76) 
The dynamic capabilities view is based on the notion that externally acquired dynamic 
capabilities attempt to bridge a firm’s capability gaps by adopting a process approach: 
and by acting as a buffer between firm resources and the changing business environment 
(Teece et al., 1997). According to Helfat and Peteraf (2003) dynamic resources help a 
firm to adjust its resource mix thereby enhancing its innovative capabilities which 
underpins its ability to make new innovations. More recently, Freeman et al. (2010) 
proposed an inspirational model for rapid knowledge development for smaller  
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born-global firms. Their model, similar to the dynamic capabilities concept extends the 
resource-based view (RBV) and network theory specifying the level of interaction 
required for the development of the new knowledge process to occur in rapidly 
internationalising smaller born-global firms. Freeman and others instrumental model is 
illustrated in Figure 1. 
Building on the ideas by Freeman et al. (2010) the new theory of ‘knowledge and 
innovative capability development’ for small born-global bio-tech firms is developed as a 
result of inference from new empirical evidence and secondary data. The new model is 
anchored on the model of rapid knowledge development for the smaller born-global firm. 
Adjustments to Freeman et al. inspirational model are made so that the new framework 
adequately explains the process of acquiring innovative capabilities specific to small 
born-global bio-tech firms. The intention is not to undermine the categorisation of the 
concepts contained in the model of rapid knowledge development for smaller born-global 
firms but rather, to adapt it so that it suites the emerging phenomenon in the bio-tech 
sector. Learning from Gerring’s (2001), Turnbull’s (1987), Andersen’s (1983) and 
Bhowmick’s (2004) critical analyses of the stages models it is a plausible thing to adjust 
a theory to meet the specific needs of the research phenomenon. The scholars suggest that 
contextual range, i.e., the scope, reach and stretch of a concept determines whether it 
needs to be adjusted to accommodate and to maximise its performance. Indeed, when 
examining specific units of a phenomenon e.g. born-global bio-tech firms being 
examined for this study, their contextual range can be a decisive factor in terms of the 
extent to which the new conceptual framework can be generalised (Gerring, 2001; 
Sartori, 1970). This is consistent with the views of Yin (2003, 2009) who argues for 
analytical generalisation of case-oriented research strategy. 
Yin (2009) suggests that analytical generalisation denotes a process where 
generalisation takes place from data to theory rather than to population. 
3 Approach 
To inform the process of theory-building the author uses a multi-case approach (Yin, 
2009). The main focus is on small born-global bio-tech firms in the East Midlands region 
of the UK. Yin (2003) and Stake (1995) advise that to avoid pursuing a study that has too 
many objectives, it is necessary to determine your case(s). From that perspective, the 
author uses a technique known as case-binding which includes: using time and place 
(Creswell, 2003); time and activity (Stake, 1995); and by definition and context 
(Huberman and Miles, 1994). Baxter and Susan (2008, p.546) support the use of a  
case-binding technique claiming that, ‘binding the case will ensure that your study 
remains reasonable in scope’. Data is collected from a systematically selected sample of 
five biotechnology firms identified as having an international flair. Expert opinion is also 
sought from three key science research institutions in the East Midlands region of the UK 
that were identified as ‘champions of innovation’. The main reason for using the  
multi-case research approach for this study is to allow the author to examine the research 
subject(s) more closely so that rich data is collected. This ensures the validity and the 
reliability of the new conceptual framework (Bellamy and Perri, 2009). More so, it 
demonstrates that the new concepts on the model of knowledge and innovative capability  
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development are grounded within and across cases of small born-global bio-tech firms. 
Results achieved in this way can be taken to be reliable (see Gerring, 2005; Huberman 
and Miles, 1994; Yin, 2009). Baxter and Susan (2008) affirm that a multiple case-study 
(Yin, 2003) or a collective case-study (Stake, 1995) allows a researcher to analyse data 
within and across settings. Crucially, the author preferred this method of research in 
particular because the evidence it generates is considered to be robust and reliable (see 
Huberman and Miles, 1994). 
4 Methodology 
Cases used in this study have been carefully chosen primarily for the following reasons: 
1 to understand the world of small born-global bio-tech firms 
2 to contribute to theoretical concepts of dynamic capabilities and networking. 
The seemingly dated but still influential work by Eckstein (1975) identified five ways in 
which case material can be useful as follows: configurative idiographic studies, 
descriptive configurative studies, heuristics case studies, plausible probes and critical 
case studies. In light of this, the author is mainly interested in heuristic case-study types 
because choosing cases using this way enabled him to develop some theoretical concepts 
which are useful in explaining the capability development process of small born-global 
bio-tech firms. 
4.1 Data collection 
The author interviewed senior managers who were responsible for spearheading their 
firm’s operational strategies. In the majority of cases the founders were also the 
CEOs/science directors of the visited firms and had vast experience in the biotechnology 
sector either from their previous posts or through years of operating as key players in  
the sector. For a period of about six to eight months commencing from November  
2011 to June 2012, a total of about 11 face-to-face qualitative discussions  
were conducted ranging from 35 minutes to 45 minutes in length with an average  
duration of about 40 mins. Table 1 on p.5 provides an array of data describing  
the small born-global bio-tech firms that were visited during the data collection  
stage. 
To achieve internal validity the author adhered to an interview guide. In cases  
where interesting lines of enquiry emerged follow-up questions were asked to  
explore the subject further. The interview guide included questions about the  
influence of various factors within the knowledge supply-chain of small born-global  
bio-tech firms identified as: business and social networks, inter-organisational  
collaborations, competence and goodwill trust, tacit and explicit knowledge, prior  
learning and absorptive capacity. The questions also focused on their personal  
experiences in business and social networks and how they developed trust in  
those relationships. The schedule guide also included questions that were aimed  
at getting the interviewees to explain the perceived risks of their operational  
strategies. 
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Table 1 Description of small born-global firms comprising the sample 
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Table 2 The outcomes of the global activities of small born-global firms 
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4.2 Analysis 
The study follows an inductive analysis style with elements of deduction. The cases 
chosen for analysis consist of CEOs/founders who are former employees of AstraZeneca 
or have vast experience in the bio-tech industry accumulated over years of operating in 
the sector. The next step in the analytical process was to investigate the sampled cases in 
order to identify patterns and trends in relation to how they generate knowledge in each 
case (Bellamy and Perri, 2009; Huberman and Miles, 1994). Yin (2009) suggests that 
using pattern-matching logic in case-oriented studies is the most appropriate technique 
for case analysis. Similar cases with identical features seen as typical born-globals were 
closely scrutinised. Taking into perspective the emerging themes, regarding the processes 
of generating scientific knowledge for small born-global firms, a causal link between 
various factors including networking, collaborating, trust, knowledge sharing, prior 
learning and absorptive capacity was formed. This way of analysing data is consistent 
with other scholars’. 
For example, Miller (1983) suggests that the process of analytic induction starts with 
a tentative hypothesis to explain something. Data collected from each firm was sorted and 
transformed into a chronological order and using thematic analysis in each case history 
(see Table 2). Thematic analysis is multi-discipline; it is used in education research 
(Cohen et al., 2007), by research clinicians (see Newfield et al., 1991; William, 1992), 
and in political science (Easterby-Smith et al., 2012). Identifiable themes for this study 
are related to business and social networks, inter-organisational collaborations, 
competence and goodwill trust, tacit and explicit knowledge, prior learning and 
absorptive capacity. The study takes the stance that these concepts are the building blocks 
to the process of developing the innovative capabilities of small born-global bio-tech 
firms operating in a hypercompetitive environment driven, among other things; by  
the wealth of information a firm can have access to Schilling (2008). The emerging 
themes from qualitative conversations enabled the author to piece together and form a 
comprehensive picture of small born-global bio-tech firm’s collective experience of 
business and social networks, inter-organisational collaborations, trust building, 
knowledge sharing, prior learning and absorptive capacity in networks. This is in line 
with Taylor and Bogdan (1984, p.131) who define themes/concepts as units derived from 
patterns such as ‘conversation topics, vocabulary, recurring activities, meanings or 
feelings’. 
5 Findings 
5.1 Innovative capabilities’ knowledge supply-chain 
This part explains the impact of the building blocks, including: business and social 
networks, competence and goodwill trust, inter-organisational collaborations, tacit and 
explicit knowledge, prior learning and absorptive capacity, on the abilities of small  
born-global bio-tech firms to build their innovative capabilities. It draws upon results 
from within and cross case analysis using the various factors, which mitigate the 
knowledge supply-chain of born-global firms, as the main themes. It also outlines the  
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authors’ propositions based on the information obtained from within and across cases. 
Secondary data analysis is also used to provide some insight and to support empirical 
evidence. This leads to the development of a model of ‘knowledge and innovative 
capability development’ for small born-global bio-tech firms. 
5.2 Business and social networks 
For small born-global bio-tech firms business and social networks are essential to their 
success. The interaction between individuals, firms or organisations with varied skills, 
experience and knowledge provides synergy for small firms with limited resources. They 
provide them with access to a wide range of economic effects (Ho and Wilson, 2006) 
including: access to specialised input and labour, novel information inflows and 
knowledge as well as access to research institutions and government R&D support 
services (Martin and Breschi, 2011). Breschi & Malebra (2005, p.47) suggest that, 
“resource pooling, risk sharing and the formation of critical masses provide incentives to 
create a group of inter-linked agents”. Powell et al. (1996, p.46) affirms that, ‘when the 
sources of expertise are disparate, collaborative R&D opens an organisation’s eyes to the 
need for accessing ideas and information from a variety of sources’. This was evident 
when the author conducted a case by case examination of their networking activities. He 
found that small born-global firms link up with other firms, scientists, research and 
academic institutions within and outside their vicinity to jointly develop new drugs and 
share technical know-how. This was reflected in the response given by the President at 
Sygnature Discovery when asked about whether his company engages in networking. He 
commented that: 
Our scientists work with other scientists from other businesses, research 
institutions and strategic alliances to jointly test and develop drugs. We work in 
a highly collaborative way e.g. in our molecule synthesising process. We have 
secure data bases that we use to share data with our partners and clients from 
wherever they might be either in San Francisco or Santiago. We have realised 
that we do not have all the capabilities and we feel that it is important to 
collaborate with other companies for example, we collaborate with Cyprotex 
Discovery. They have better knowledge about how the drug dissolves in the 
body. What is important is we share capabilities. 
We feel that we have modelled our business in a ‘hub and spoke’ model i.e. we 
are in the middle and we are networking with other companies. 
In light of this evidence, indicating that bio-tech firms in the East Midlands region in the 
UK are forging global networks to enhance their capability development, the author can 
confidently conclude that the business and social networks in the knowledge  
supply-chain of small born-global bio-tech firms significantly influence how they acquire 
scientific knowledge and technical know-how. Accordingly, Nahapiet and Ghoshal 
(1998), and Tsai and Ghoshal (1998) suggest that social capital embedded in a firm saves 
as a conduit that facilitates and enables positive conditions for the exchange of 
knowledge and the combination of resources to occur. When discussing with an expert 
working in a knowledge ‘hub’ the author was fully convinced that the business  
and social networks of small born-global bio-tech firms play a decisive role in how  
they develop their innovative capabilities. The innovation advisor, Rosamund Graves,  
commented that: 
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We help firms and industry sectors access information, opportunities and 
partners on a global scale through specialist networks and business intelligence. 
On behalf of national government agencies, we deliver programmes to 
stimulate international inward investment, technology transfer, partnering and 
access to high growth global markets for UK companies. We provide business 
intelligence and contacts to help UK firms identify and realise international 
opportunities. 
Her statement endorses that forging networks within and outside a firm’s local industry 
milieu plays a key role in the process of acquiring knowledge and technical know-how. In 
that regard, it is plausible to claim that business and social networks are part of the jigsaw 
puzzle needed to complete the process of generating novel information for small  
born-global bio-tech firms. 
Proposition 1 Business and social networks act as a catalyst for small born-global  
bio-tech firms in their process of developing innovative capabilities 
Social capital and network ties have a positive impact on international start-ups, new 
ventures and SMEs’ performance (Johnson and Vahlne, 2003; Oviatt and McDougall, 
1994, 2005). Furthermore, Hughes and O’Regan (2009) stress that for a firm to gain 
access to knowledge and technical know-how it is essential to collaborate in networks 
and engage with a range of advisors that include: scientists, academia and agencies. This 
was echoed in the conversations with the CEO at XenoGesis Ltd., and the Science 
Director at BAST Inc. Ltd. When discussing about how wide-spread their networks are 
the CEO, and the Science Director of the firms mentioned above explained that: 
I have a good network of ex-colleagues that I used to work with at AstraZeneca 
and such connections are vital for sharing scientific knowledge and technical 
know-how. I think collaborating with other businesses and academia is 
essential in the bio-tech industry and it is important that businesses join to work 
on new discoveries. That is the way things are heading towards nowadays 
given the nature of the markets. Apart from using my business or social 
connections as conduits of scientific knowledge I also publish papers. CEO at 
XenoGesis Ltd; 
And, 
I engage in networking activities both locally and internationally with firms and 
organisations in the USA, Asia for example. I personally have some contacts in 
America where my business started way back in 1998 as a model based on a 
drug development firm. Science director at BAST Inc. Ltd 
Their responses boldly underline the essence of business and social networks. Indeed, the 
evidence is strong and this indicates that in the globalised markets of the biotechnology 
sector, going it alone is no longer the best option because it is so difficult for small firms 
to possess all the necessary capabilities. Lasserre (2012) argues that firms can benefit in 
globalised networks by accessing and taking advantage of geographical clusters of 
knowledge creation and development. In that sense, business and social networks of 
small born-global firms can be seen as channels through which they can access scientific 
knowledge and technical know-how. Considering the suggestions from the CEO of 
XenoGesis, and the Science Director at BAST Inc. Ltd quoted above it is plausible to 
conclude that small born-global bio-tech firms use networks to generate knowledge so as 
to leverage their internal science capabilities with a view to discovering new drugs. Thus,  
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giving them greater flexibility needed to survive in a hypercompetitive business 
environment (Schilling, 2008; Lasserre, 2012; Hisrich, 2012). Schilling (2008, p.158) 
further affirms that ‘as firms forge collective relationships they weave a network path 
between them that act as a conduit for information and other resources’. 
Funding institutions are also a key player in the networks of small born-global firms. 
Mobius Life Sciences – an investment arm of BioCity Nottingham (BCN) work alongside 
Nottingham City Council (NCC) to provide financial support ‘seed investments’ in high 
potential life science businesses. Crocker (2010) explains that the investment arm has a 
highly experienced and well networked team. This gives the author strong belief that 
financial support for bio-tech firms significantly boosts their limited resources and it adds 
value to their businesses which ultimately enhances their capacity to innovate. The CEO 
at Haemostatix said this: 
While business networks facilitate the flow of novel information, financial 
investments are a ‘shot in the arm’ in that they also provide a company with the 
opportunity to develop innovative technology. In our case we were presented 
with the opportunity to develop an innovative haemostat technology. 
This shows that business links that include funding institutions are the bedrock for small 
firms seeking to make crucial innovations. What is happening in the East Midlands has 
striking resemblance to networking activities documented elsewhere, e.g., in the Golden 
Triangle of Cambridge, London and Oxford, the Silicon Valley and the Boston 
metropolitan area. The Cambridge Cluster Report of 2004 reports that over the last 
decade the cluster has acted as a magnet attracting supportive infrastructure comprising 
of number of key players such as: venture capitalists firms, banks, marketing experts and 
patent agents. 
5.3 Competence and goodwill trust 
Strong relationships that allow the free flow of information to occur were found to exist 
between parties involved in a well-established network and trust was the most important 
component of that process. Results from within and across cases show that small bio-tech 
firms trust their collaborating partners based on their technical prowess (competence 
trust) and good intentions (goodwill trust) within the life science sector. In this  
study, the author uses Blomqvist’s (1997, p.3) definition of trust expressed as  
an ‘actor’s expectation of the other party’s competence, goodwill and behaviour’.  
Consistent with Blomqvist’s definition, Gubbins and MacCurtain (2008) claim  
that to trust an individual’s ability is to trust in his or her skill and competencies  
to do the job. Evidently, all the participants in this study indicated that trust is  
established when they know that their collaborating partner is skilled and very  
capable. Especially, in a specific area of science which complements their knowledge  
gaps. 
In a discussion with the CEO at XenoGesis about how trust is developed in networks 
he expressed that: 
We build trust by first conducting due diligence (i.e. we do a search on their 
level of technical capabilities, their reputation which we get from people who 
have worked with them before). In other words we look for partners who have 
higher skills and are well established/known in the industry. This is all done in 
a trial and error method. 
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The interpretation from this statement, which is supported in the literature (see 
Blomqvist, 1997; Sengun, 2009), demonstrates the relevance of competence (technical 
capabilities, skills and know-how) in the biotechnology sector and it shows that it is a 
necessary antecedent and basis for trust in professional relationships within a business 
context. Networking with organisations that have better skills levels is an important 
factor in building trust in the bio-tech sector particularly, in instances where potential 
partners are assumed to have technological knowledge and competences (Blomqvist, 
1997). Furthermore, the statement highlights that the reputation of a partner, including: 
moral responsibility and positive intentions towards the other, was an important factor 
that influenced his firms’ decision to accept a potentially vulnerable position (risk 
inherent by partnering). Welter (2012, p.194) claims that ‘trust is seen to assist in 
lowering the transaction costs of commercial actions and the risks inherent in 
entrepreneurship’. In the majority of the firms in the sample, trust was built in escalating 
series using a ‘trial and error’ method. This discovery contributes to the social exchange 
theory (Pretty and Ward, 2001; Inkpen and Tsang, 2005; Whitner et al., 1998) which 
suggests that information, advice, social support and recognition are important means of 
building trust created through repeated interactions and reciprocity. In addition to the 
main meaning of the social exchange theory, when asked about how trust was builtin his 
firm the President at Sygnature Discoveries stressed that: 
Our partners I guess they also do a due diligence to assess whether we fit into 
what they are looking for. With our alliances we are well connected actually, 
before establishing this connection we first test the partners trustworthiness 
through engaging in small projects and we take it step by step until we are fully 
convinced that a stronger partnership can be established. Competence and 
reputation play a key role in building new networks. 
This is further evidence suggesting that in order to build trust a wide scope of information 
is necessary for small born-global bio-tech firms because different types of information 
including relational-emotional, socio-economic and tacit-explicit significantly impact on 
the trust experienced. With all the firms in the sample, trust was naturally developed 
within their business community at BCN but with organisations and institutions outside 
their locality there was more of ‘trial and error’ requiring a lot of information search. The 
process of due diligence was done mainly to test the trustworthiness of a potential 
business partner in particular, their intentions which is related to the goodwill dimension 
of trust. The process of testing a partners’ trustworthiness through small projects was 
targeted at identifying positive or negative signs and signals which Blomqvist (1997) 
claims are visible and easier to evaluate when the relationship is developing. This was 
found to be a vital activity for small born-global firms and it was critical to how they 
developed innovative capabilities in newly established networks. Responding to the same 
question on trust building in newly formed networks which they develop in a global 
context, the CEO at XenoGesis stressed that: ‘it is very important to try different 
combinations to ensure that we end up working with people who share the same values as 
us’. In this case it was the CEO’s envisaged strategy that his organisation should develop 
trust with its partners based on the soundness of their strategy and vision. 
In the relevant literature (Mishra, 1996; Sydow, 1998), the competences of an 
organisation are seen as a basic and profound source of trust in asymmetric technological 
partnerships. Blomqvist (1997) suggests that competence trust may be born out of a 
firm’s technical capabilities, financial resource-base and partnering competences. Thus, 
the author proposes that: 
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Proposition 2 For small born-global firms competence and goodwill trust are major 
factors that reduce friction and perceived risks allowing the free flow of 
fluid scientific knowledge and technical know-how through established or 
newly developed business partners. 
The most common form of trust that was evident in the research sample was the sense of 
benevolence; meaning that scientific knowledge and technical know-how developed with 
partners were protected within the trusted group/network (Hoy and Tschannen-Moran, 
1999). The firms relied on the goodwill of their partners to act in the best interest of both 
parties. In on-going relationships future behaviour was not specified but there was a 
mutual attitude of goodwill. As illustrated in the ‘knowledge and innovative capability 
development model’ on p.17, trust was the basis on which inter-organisational 
collaborations stemmed from in the capability development process of small born-global 
bio-tech firms. More importantly, trust was a pre-requisite to knowledge sharing and the 
exchange of technical know-how. 
5.4 Inter-organisational collaborations 
Data collected from sampled firms demonstrates that there was a strong relationship 
between collaboration and innovation. Through conducting a detailed case by case 
analysis it was found that the main reason why small born-global bio-tech firms 
collaborate with other firms/research institutions was to learn from them in order to 
enhance their innovative capabilities. Zucker et al. (1998) posit that learning underpins 
organisational innovation and according to Basile (2010, p.3) innovation ‘is a complex 
and interactive process that involves a variety of actors’. In the biotechnology sector 
where scientific knowledge is both complex and ever-expanding in search of new 
discoveries the sources of expertise are widely dispersed. In such sectors, Powell et al. 
(1996) postulates that the locus of innovation is usually found in networks of learning as 
opposed to going it alone. The CEO at Critical Pharmaceuticals revealed that: 
In the bio-tech industry you need various skills and knowledge, in addition to 
our in-house knowledge we collaborate with other institutions such as 
universities, other companies – large or small both locally and internationally 
and along with that we have different levels of collaboration. We collaborate 
with companies in the USA, EU. We also have intense collaborations with 
companies near to us who have expertise in areas of interest we therefore work 
with them to access the expertise that we do not have. 
This evidence powerfully demonstrates that small born-global bio-tech firms maintain a 
broad scope of interactions with a wide range of actors in the bio-technology sector with 
a view to complement their knowledge bases. Scholarship on inter-organisational 
networks argues that firms should look further than their own boundaries to acquire 
strategic resources (Subramanian and Soh, 2010; Feldman et al., 2002). The traditional 
model of large pharmaceutical companies where all research activities were done  
in-house is slowly fading into the horizon. The managing director at BioCity Nottingham 
(BCN) observed that: ‘The large Pharma used to employ a large number of scientists 
under one roof and that structure is fragmenting giving rise to the formation of smaller 
research-based organisations’. The re-structuring exercise happening at AstraZeneca and 
Boots in the East Midlands and at Lund in Sweden typifies this. The pharmaceutical 
   
 
   
   
 
   
   
 
   
    A new model of knowledge and innovative capability development 43    
 
    
 
 
   
   
 
   
   
 
   
       
 
giants are undergoing a strategic shift towards outsourcing their R&D activities to small 
bio-tech firms. 
This heralds a significant move towards more collaboration between organisations in 
the biotechnology sector where smaller firms such as those investigated for this study are 
taking the centre stage. Large pharmaceuticals continue to provide marketing, 
commercial capabilities and financial resources. Similar studies (see Stuart et al., 2007; 
Zucker et al., 1998) have reported a growing trend, in the biotechnology, sector where 
small firms are being contracted to do the research for large pharmaceutical companies. 
More recently, Kang and Park (2012, p.70) reported that ‘while the new biotechnology 
firm specialises in specific types of knowledge, products and applications large 
established firms have expertise in the commercialisation of new inventions that involve 
large scale production, marketing and distribution, and regulatory processes’. The CEO at 
Critical Pharmaceuticals expressed that: 
We acquire financial support to back up our products, expertise, marketing, PR, 
scientific knowledge and these are things that we do not have in house and they 
are needed to achieve our goals. The only way to achieve this is through linking 
up with people who have been there and done it and are well established in the 
market. 
This highlights the significance of inter-organisational collaborations in terms of: 
1 bridging the knowledge gap of small born-global bio-tech firms 
2 enabling them access to markets 
3 providing them with financial back-up 
4 getting help from science experts who have vast experience in life science. 
In support of these findings, Schilling (2008) makes similar observations and she 
postulates that, small biotechnology firms form partnerships with large pharmaceutical 
firms for their mutual benefit: pharmaceutical firms gain access to the drug discoveries of 
the biotechnology companies and likewise small bio-tech firms gain access to the capital 
resources, manufacturing and distribution capabilities of these large pharmaceutical 
firms. The author discovered a growing trend of these mergers and consolidations. For 
example, Critical Pharmaceuticals worked closely with academia to develop a highly 
innovative formulation of teriparatide. The University of Leicester (UoL) played a 
crucial role in supporting Haemostatix Ltd during its early stages of development. The 
firm received support in the form of clinical laboratories as well as opening up links with 
other institutions and organisations. As a result of Haemostatix Ltd’s links with the UoL, 
it received start-up funding of £250,000 from The Lachesis University Challenge Fund 
and an initial investment from NESTA. The founder of Haemostatix expressed her 
profound gratitude in 2006 when her organisation received support from Quester, 
‘Quester has worked with us (Haemostatix Ltd.) since 2002 and we are pleased to have 
their financial support and strategic input to take the business forward’. 
Proposition 3 Inter-organisational collaborations are an important step in the knowledge 
supply-chain of small born-global firms and they influence their process 
of developing innovative capabilities 
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However much seemingly important inter-organisational collaborations are; the study 
discovered that trust played a significant role in allowing the exchange and transfer of 
knowledge between collaborating partners to occur. It was found that for small  
born-global bio-tech firms with global foci; their inter-organisational collaborations were 
based on competence and goodwill trust. Şegun and Önder (2011, p.796) claim that, 
‘trust in competence refers to the perceptions of the trust or concerning the trustee’s 
technical, cognitive and communicative competences’. At the inter-organisational 
exchange level small born-global firms collaborated with organisations they believed to 
have expertise and experience. This enabled them to successfully develop or test drug 
combinations. 
When the president at Sygnature Discovery was asked about the importance of  
firm-based competencies and goodwill in trust building this is what he had to say: 
We build trust with potential partners based on their science and technical 
capabilities. We also receive advice from BioCity, Medilink and UKTI about 
potential partners and I guess it is part of due diligence. 
The above statement also brings to light the fact that firms intending to enter into 
partnerships with other firms can use a third party to gather information about their 
scientific capabilities and technical know-how, more so, for those which are 
geographically distant. In all the firms that took part in the interviews this was important 
as their intentions were to work with global partners. When seeking global partners these 
firms relied on the advice they received from BCN, Medilink East Midlands, UK Trade 
and Investment (UKTI), and from their established connections. The innovations 
manager at Medilink explained this more fully when asked about the role her 
organisation plays in facilitating inter-organisational collaborations. She stated that: 
We would facilitate for companies that intend to relocate to the East Midlands 
by providing them with the necessary information. We support both domestic 
and international organisations and recently we had a company that came from 
India intending to establish in the East Midlands. In that case we supported 
them by providing them with information to enable them to achieve their goal. 
Bachmann and Inkpen (2011) agree that in cases where face-to-face interactions with a 
potential partner are not possible a third party may operate as a guarantor. The managing 
director at BCN echoed these sentiments explaining that for their tenants they ‘guarantee 
a certain level of competence and quality of a potential partner but after that they take a 
step back and let people work and learn on their own’. A strong bond was gradually 
developed between collaborating firms, whether local or foreign, over a period of time 
through a ‘trial and error’ method. When the relationship got stronger the level of trust 
was increased accordingly thereby allowing the free flow and exchange of scientific 
capabilities as well as technical know-how. In the literature regarding trust, high levels of 
trust are associated with a decrease in perceived risk and they are cast as being 
fundamental to the formation of strong relationships. Thus, strong relationships are a 
precursor to trusting that a business partner will act in the best interest of both parties 
(Şegun and Önder, 2011). Evidently, some form of connection existed between firms 
which used a pre-existing business network such as BCN as their base but for partners 
outside their locality a ‘trial and error’ method taking the form of smaller projects was the 
main method of assessing the trustworthiness of prospective partners. As such the 
author’s fourth proposition is that: 
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Proposition 4 Small born-global bio-tech firms build trust with their prospective 
partners in escalating series basing it on their partner observations from 
inter-organisational collaborative projects. 
5.5 Tacit and explicit knowledge 
The process of acquiring knowledge is a very complex process which involves 
participating in generating and disseminating it in a way that benefits all the people 
involved (Powell and Grodal, 2005). There was cogent evidence indicating that small 
born-global bio-tech firms aim to develop stronger ties with local and international 
partners in order to ensure that they continue to receive crucial scientific knowledge. 
Ideas and knowledge generated from science-related projects involving sampled firms 
were codified and retained in the firm for future developments. This was reflected in the 
discussion with the CEO at Critical Pharmaceuticals regarding how his firm managed 
data accumulated from collaborative projects. 
To this end, he explained that: 
From a scientific perspective for a lot of the key projects we trap the knowledge 
that people have used in a project and we have project management systems to 
make sure that we capture all the knowledge e.g. by monitoring projects, gantt 
charts and project reports. 
Managing scientific information this way was not only unique to Critical 
Pharmaceuticals. All the firms echoed the same sentiments. They also revealed that 
knowledge management was a crucial part of their drug discovery process. The findings 
are consistent with a number of scholars (see Daud and Yusoff, 2010; Hughes and 
O’Regan, 2009; Nonaka et al., 2000) who discuss the concept of knowledge 
externalisation. They postulate that externalisation allows knowledge that exists in the 
head of the knower to be codified into rules, specifications and formulas that can be used 
and become the basis of new knowledge. All the firms that participated in the discussions 
regarding developing innovative capabilities in the biotechnology sector placed great 
value on both tacit and explicit knowledge they acquired from their trusted partners. The 
firms went beyond their immediate environment in search of a new context and a new 
world-view. Todtling et al. (2009) suggest that sector-based innovations are not bound by 
geographical location; they often have international or even global reach. Global 
networking in search of new insights was a dominant characteristic in the majority of the 
firms that took part in the survey. Nonaka et al. (2000) point out that the process of 
creating knowledge is a continuous one and it transcends beyond one’s immediate 
environment. In a discussion with the CEO at Critical Pharmaceuticals he acknowledged 
that since his firm started to operate 15 years ago he has witnessed a significant 
transformation in the way his business now generates new knowledge. He emphasised 
that: 
The way we do business in the bio-tech industry has changed; when I started at 
Critical Pharmaceuticals most of the knowledge was only in-house. We now 
have access to a lot of external resources and nowadays there is a huge push 
towards accessing knowledge from outside for non-core areas. I would say the 
industry has changed somewhat it is now more open and there are a lot of 
collaborations with academics and research institutions and I think that has 
been good for the industry. 
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From that perspective, the interaction between individuals or a group of firms is vital in 
terms of facilitating knowledge transfer. As tacit knowledge exists in the head of the 
knower (Hughes and O’Regan, 2009), small born-global bio-tech firms work in 
collaborative projects with scientists, research institutions and other firms with a view to 
stimulate its transfer. Porter et al. (2005) point to the amalgamation of intellectual capital 
of clinical researchers and research academics as key to the success of the commercial 
world of biotechnology in the Boston metropolitan area. Similarly, Todtling et al. (2009, 
p.67) claim that, ‘universities are regarded as key knowledge sources of firms for more 
advanced innovations’. This bears striking resemblance with the patterns of knowledge 
development emerging from the East Midlands region in the UK. There is cogent 
evidence of the existence of strong ties and relational-like trust in the sampled firms that 
are located at BCN, the region’s science ‘hub’. 
Based on their shared values and common beliefs invested at BCN the firms naturally 
formed business connections and the intentions of all the firms were predictable. 
Boschma (2005), and Asheim and Gertler (2005) make similar observations and they 
highlight that interactions that occur in an institutional context facilitate the transfer of 
tacit and explicit knowledge. Through strong ties and relational-like trust, knowledge was 
freely exchanged. Discussions with the participants yielded two main forms of 
knowledge-sharing in the biotechnology sector. One form of knowledge-sharing that was 
clear was the idea of complementing each other’s core competences. The strategy was 
evident across all the sampled cases. The collaboration between Critical Pharmaceuticals 
and PolyTherics is an example of complementary knowledge assets. 
Critical Pharmaceuticals specialises in injectable products and PolyTherics Limited is 
an innovator in precision improvement of proteins and peptides. In that sense, the 
company’s expertise and knowledge capabilities complements Critical Pharmaceuticals’ 
technology of human injectable drugs. The second form of knowledge-sharing was in the 
mould process re-configuration. It is, however, important to note that in both forms of 
knowledge-sharing the process of transferring knowledge occurred after the 
establishment of the intentions of the partnering firm(s) or institution(s). BAST Ltd. as a 
contract research organisation (CRO) exchanged knowledge with its collaborating 
partners by re-arranging science apparatus in such a way that it enhances new drug 
discoveries. When responding to the question about how his firm’s collaborative partners 
utilise the knowledge acquired in collaborative drug discovery projects the science 
director at BAST Ltd explained that: 
We use the information that we share with them to enhance their innovations 
and to accelerate their business processes. Basically, our ideas would change 
the next developments that they have which helps them to reduce costs and 
even sharpen their innovations and the way they put their resources together 
e.g. their operations and product development strategies. 
With the first form of knowledge-sharing where both parties provide valuable input to the 
project, there was high commitment to generate both tacit and explicit knowledge. The 
firms developed relational capacities pooling together the skills of specialised participants 
who ultimately played an important role in the overall flow of information and resources 
in the network. The exchange and transfer of specialised scientific knowledge and skills 
between the firms engaged in collaborative projects or in the wider network at BCN had a 
significant impact on how they build their innovative capabilities. This brings to light the 
fact that both tacit and explicit knowledge are important factors that have an impact on 
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the knowledge supply-chain of small born-global bio-tech firms. Nonaka and Takeuchi 
(1995) suggest that the creation of new knowledge is predominantly characterised by the 
interaction between two main forms of knowledge, i.e., tacit and explicit knowledge. 
Thus, the author proposes that: 
Proposition 5 Tacit and explicit knowledge generated in the collaborative projects of 
small born-global bio-tech firms influence how they develop their 
innovative capabilities. 
5.6 Prior learning and absorptive capacity 
Building on earlier studies by Cohen and Levinthal (1990), Jansen et al. (2005) on prior 
learning and absorptive capacity evidence from qualitative conversations with the 
founders/science directors of small born-global bio-tech firms suggests that their 
experience in science was crucial in the process of assimilating useful scientific 
knowledge. Small born-global bio-tech firms gather science-related information from a 
wide range of sources and the science knowledge levels of their management teams 
played a crucial role during the process of acquiring information which was specific to 
their needs. The CEO at XenoGesis explained this more fully when asked about the 
importance of prior learning in terms of understanding the specific knowledge that is 
useful for their science in business and social networks that span beyond their proximity. 
This is how he put it: 
One has to understand the relevance of the acquired knowledge to science and 
experience in that respect plays an important role. Given the experience our 
team of experts have in bio-tech we are in a better position to acquire the 
science that is necessary for our service. 
The same sentiments were echoed by the CEO at Haemostatix he explained that: 
Experience in science plays an important role when it comes to selecting the 
right type of knowledge that is needed to develop new technology. 
This demonstrates that their ability to recognise and assimilate external knowledge was 
crucial to their process of developing innovative capabilities. Cohen and Levinthal (1990) 
argue that a firm’s ability to evaluate and utilise information is heavily influenced by 
prior related knowledge. Within case analysis revealed that for all the sampled firms, 
their management structure was composed of individuals who had vast experience in 
science and had worked for large bio-pharmaceutical firms. As such, their wealth of 
experience was vital in terms of understanding the knowledge gap in their firms. To get a 
different perspective on this the topic about prior learning and absorptive capacity was 
presented to an innovation expert at Medilink East Midlands as a point of discussion and 
she commented that: 
Working with other organisations to share knowledge and ideas is great, but 
what is important is that one has to have some understanding about the 
knowledge that will help his/her business to take that one step forward. 
In all of the above statements, made by the participants, there is clear evidence that 
experience and prior learning have a significant impact on how a firm selects useful 
knowledge to complement its knowledge gap. Evidently, working with other firms or 
science institutions whose complementary foci is at some cognitive distance results in the  
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accumulation of vast amounts of information but recognising what a firm needs 
significantly increases its capacity to innovative. Indeed, working in collaboration 
accelerates the firm’s process and product improvements. Schilling (2008) suggests that a 
firm’s prior related experience shapes its ability to recognise the value of new 
information and its ability to utilise that information effectively. Thus the author proposes 
that: 
Proposition 6 The experiences of small born-global bio-tech firms are essential to their 
ability to recognise, assimilate and apply knowledge from their business 
and social relationships in a way that enhances their capacity to innovate. 
It is also important to inform the reader that the concept of learning has not been fully 
explored here because it is beyond the remit of this study. Although the concept has been 
discussed in a limited fashion it has been an important part of the process of 
understanding its role in the development process of innovative capabilities small  
born-global bio-tech firms. Following an in-depth account of various factors within the 
knowledge supply-chain of these entrepreneurial ventures the author proposes a refined 
conceptual framework of knowledge and innovative capability development. 
6 A model of knowledge and innovative capability development 
The formation of theories in social science is fundamental to how we explain what we are 
trying to talk about (Gerring, 2005). Precisely, theories are instrumental in social science 
as they help us to make connections between the world people live in and how they 
interpret it (Gerring, 2001). Bellamy and Perri (2009, p.90) point out that regardless of 
one’s research philosophy developing an adequate conceptual framework provides a 
roadmap that guides how the researcher explores the social world and for those working 
with variables and correlations they are able to ‘establish valid measures and apply them 
reliably’. Building on the inspirational work of Freeman et al. (2010) regarding  
how smaller firms rapidly develop new knowledge in their internationalisation  
process; this study proposes a new improved framework for small born-global bio-tech  
firms. 
Figure 2 Knowledge and innovative capability development model 
 
Source: Modified from Freeman et al. (2010) and author’s ideas 
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Using existing literature, empirical evidence from within and across cases the study 
proposes the ‘knowledge and innovative capability development model’. Siggelkow 
(2007) affirms that using rich data acquired through closely examining instances of 
occurrences in cases can inspire new ideas in theory construction. In the same vein, 
Eisenhardt and Graebner (2007) express that the output of case-oriented research designs 
take various forms including: a new concept, theoretical construct, conceptual 
framework, propositions, and in other cases a mid-range theory. Similarly, Ridder et al. 
(2009) agree that case studies have the potential to uncover unusual phenomena and of 
repeating or countering the replication of findings of other cases which eliminates 
alternative explanations and elaborates the emerging theory. From these perspectives the 
author presents Figure 2 which neatly illustrates the proposed conceptual framework as a 
result of new evidence. 
Small born-global bio-tech firms operate in a very complex and sophisticated 
business sector which is exceedingly dynamic. Therefore, it is imperative that they 
formulate strategies to enable them to continue to produce innovative life-saving 
products. The primary aim should be to enhance their innovative capabilities which 
enable them to make crucial innovations (Powell and Grodal, 2005). The firms used in 
this sample were all resident at BCN implying that they exist in a network which is 
already established where they have developed strong business and social ties. They 
demonstrated an entrepreneurial flair by venturing into the global markets in search of 
global partners. As denoted in Figure 2, the establishment of business and social 
networks, described as innovation networks by Powell and Grodal (2005), is the key 
building block within the knowledge supply-chain of small born-global bio-tech firms. 
Elfring and Hulsink (2003) make an important observation about entrepreneurial firms by 
suggesting that networks (business and social) contribute significantly to the venturing 
process of entrepreneurial small firms by presenting them with access to knowledge and 
unique capabilities. In their local network at BCN and the wider East Midlands region the 
firms were aware of the competences and the intentions of their potential collaborative 
partners thus, trust was built at a very early stage. This quickened the process of 
knowledge transfer as well as the exchange of technical know-how. So, established 
networks are credited with building trust which leads to inter-organisational 
collaborations. Established networks also led to newly-formed business and social 
networks (see Davis, 1970; Wall, 2009). In newly developed networks, trust was quite 
superficial and in some cases non-existent. 
Therefore, for R&D institutions, firms or scientists located in foreign markets  
inter-organisational collaborations in the form of smaller projects were used as ‘trial and 
error’ conduits to test the trustworthiness of the prospective partner. Indeed, in their 
process of developing innovative capabilities small born-global bio-tech firms embarked 
on a number of different, often unsuccessful, configurations and techniques before 
finding the right combination that worked well for them (Lichtenthaler and Lichtenthaler, 
2009). Schilling (2008) explains this process of experimentation and learning more 
clearly asserting that this stage in the knowledge supply-chain is vital in the sense that it 
allows the firm to build a base of knowledge about how key components behave, what 
alternatives are more likely to be successful than others, and what types of projects the 
firm is most successful in. Small bio-tech firms were forced to adopt the experimentation 
approach because of the dynamic nature of the biotechnology sector i.e. its heavy reliance 
on highly fluid scientific knowledge and technology to make new drug discoveries and  
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the speed with which these types of firms form and disintegrate required high levels of 
trust (Maxwell and Levesque, 2011; Welter, 2012). This strongly suggests that trust is 
ever-more critical for the transient and the high speed environment of the small  
born-global bio-tech firms as the basis for knowledge sharing (Freeman et al., 2010).As 
such, trust was built in escalating series because of the risks associated with developing 
new partnerships. Sitkin and Pablo (1992) discuss risk perception by referring to the 
assessment of the risk inherent to a situation. In all of the five small born-global firms the 
assessment of the risks associated with knowledge-sharing with new partners was done in 
a carefully orchestrated logical step-by-step approach. Once trust was built, whether in 
established or newly developed business and social networks, it paved the way for 
effective knowledge-sharing. Similarly, Hill (1990) claims that, it is highly likely that a 
firm will engage in knowledge transfer with partners who have demonstrated their 
trustworthiness and co-operative abilities in their other relations. 
The process of knowledge-sharing is embedded in pre-existing business and social 
connections. Hutchings and Michailova (2006) suggest that sharing knowledge depends 
on the pre-existence of insider relationships and a disposition towards cooperative 
interdependence. Scholarship on entrepreneurship generally agree that small firms with 
limited resources have a tendency to soak as much information as is possible with the 
hope that something magical will materialise. The proposed model suggests that for small 
born-global firms prior understanding of the complementary resources needed for the 
firm to develop new life-saving drugs or technical products is essential otherwise 
engaging in collaborative projects will count to nothing in the way of innovations. The 
underlying assumptions of the model are that, by acquiring new scientific knowledge and 
technical know-how the firm enhances its innovative capabilities that underpin the 
development of new products and services in the life science industry. Furthermore, the 
process of generating innovative capabilities is directly anchored on the greater 
connectivity and enhanced collaborations in the life science’s innovation ‘ecosystems’ 
described by Booth (2009, p.705) as a ‘brave new world’. Indeed, the connectivity and 
collaboration between various actors within the East Midlands network performed a key 
part in the process of ensuring continued development of scientific knowledge and 
technical know-how by providing financial support and infrastructure. BCN provided the 
firms specialised premises with state of the art lab equipment while NCC and Mobius 
provided seed funding to promising ventures. A similar observation was made by Laine 
et al. (2008), the scholars maintain that, at the core of innovation ‘ecosystems’ are firms 
and enterprises which are involved in innovative collaborations with academic 
institutions and investors. A convincing argument regarding the logic behind facilitating 
the development of innovation ‘ecosystems’ similar to those appearing in the East 
Midlands region, was made by Hautamaki (2007). Hautamaki argues that the 
‘ecosystems’ approach places great emphasis on close cooperation and a culture of 
creativity which refers to adventurism, entrepreneurship and innovativeness. The 
evidence is clear in the East Midlands region suggesting that born-global bio-tech firms 
are involved in local innovation ‘ecosystems’ that considerably influence the movement 
of knowledge within their knowledge supply-chain. Adner (2006) insists that an 
innovation ‘ecosystem’ facilitates integration risks of having the solution adopted across 
the value-chain. This is consistent with Bramwell et al. (2012) conceptualisation of an 
innovation ‘ecosystem’ approach. The scholars see it as a sophisticated way of  
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holistically looking at mechanisms that interact within an economic system. Crucially, for 
policy makers such innovation systems will ‘enable them to pay close attention to the 
collaborative, inter-dependent nature of the innovation processes and to identify the best 
means of stimulating productive networks and relationships within and across disciplines 
and sectors of comparative advantage’ [Bramwell et al., (2012), p.49]. Additionally, 
Wolfe et al. (2011) describes the regional knowledge ‘ecosystem’ approach insisting that 
it leverages regional infrastructures with a view to stimulate/support regional innovation 
processes through the collaborations of multiple partners that include: research and 
academic institutions, investors, other firms and investors. Wolfe et al. description of 
regional knowledge ‘ecosystems’ has a striking resemblance with the innovation 
‘ecosystems’ within the East Midlands region that are supporting the process of 
generating innovative capabilities denoted on Figure 2. 
7 Discussions 
7.1 Rationale for stretching the model 
Freeman et al. (2010) invite other scholars to carry out more research to develop further 
their model of rapid knowledge development for smaller born-global firms. This stretches 
its reach. In particular, they recommend the need for further studies to refine their 
conceptual framework and its applicability to the internationalisation processes of smaller 
born-global firms, and the network perspectives. As such, the advent of bio-tech firms 
with an international flair necessitates the modification of their model to accurately 
capture the specific world of this new phenomenon. The firms build their innovative 
capabilities by participating in evolving global R&D networks (Simba, 2012) hence; the 
need to develop a conceptual framework that adequately captures the changing terrain. 
As Swain (2012, p.12) noted, ‘The Big Pharma model is undergoing a painful evolution, 
moving from competition to collaboration, from one-size-fits-all to more tailored 
approaches, and a longer-term view of basic research’. During the restructuring phase 
occurring in Europe and America (Rafols et al., 2012); scientists are taking centre stage 
in global R&D activities. They are forming science-based firms (small born-global  
bio-tech firms) which are exceedingly productive (Simba, 2012). Evidence in the 
literature, from within and cross cases demonstrates that the business and social 
connections of the scientists which were developed during their previous employment 
have become part of the structural dimension of their new ventures. According to Munos 
(2009), the business and social connections of these scientists are used as channels for 
scientific knowledge, technical know-how and market-related intelligence. Their 
cognitive dimension consists of experienced scientists implying that they have vast 
knowledge in science. As such, Freeman’s et al. (2010) model was stretched to 
accommodate this new empirical evidence. By doing so, the newly constructed model of 
knowledge and innovative capability development significantly contributes to the 
understanding of the concepts of dynamic capabilities and networking theories that 
already exist (e.g., Rogers, 1962; Johnson and Vahlne, 1977; Teece et al., 1997; Freeman 
et al., 2010). 
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8 Conclusions 
The new propositions and a revised model presented in this paper increase the 
performance of Freeman’s et al. (2010) model of rapid knowledge development for 
smaller born-global firms. The new model develops new and alternative understanding of 
the new types of bio-tech firms developing in the biotechnology industry which are 
conceived with global foci. The study reveals the importance of horizontal networks and 
the interplay between firms, research institutions and academics that have complementary 
technologies and science within the knowledge supply-chain of small born-global  
bio-tech firms (Schilling, 2008). The author believes that the newly formulated theory of 
innovative capability development contributes to the understanding of the network 
approach which focuses on specific, well-selected relationships in the innovation process 
with specific actors within the same innovation milieu and beyond (Cooke, 2003; Breschi 
and Malerba, 2005). The study also demonstrates that for small born-global firms to 
receive and share tacit and explicit knowledge some form of trust between the 
collaborating parties has to be established. In that sense, competence trust, i.e., trust 
which is based on the scientific and technical capabilities of the prospective partner and 
goodwill trust referring to the intentions of the prospective partner were identified as 
critical to inter-organisational collaborations that occur in the biotechnology sector. 
The study also brings to light that trust, in the collaborative projects of bio-tech firms, 
is built in escalating series. In established science centres relational-like trust naturally 
exist among resident firms. But, in newly developed networks trust exists casually or 
does not exist at all. With newly developed relationships the study found that the ‘trial 
and error’ method was evoked. The process was observed as starting with firms engaging 
in smaller projects aimed at testing the trustworthiness of a prospective partner. This 
potentially led to more collaboration(s). This observation is consistent with Schilling 
(2008) who claims that experimenting by linking up with different partners during the 
stage of establishing a partnership is necessary for high-tech firms as collaborating is not 
without risks. Within the knowledge supply-chain of small born-global bio-tech firms the 
previous learning and sector-based experiences of the CEOs, bio-entrepreneurs or science 
directors are crucial in terms of absorbing specific capabilities or choosing the right 
partner with specific skills or knowledge that complements their firm’s internal 
capabilities. As much as the research approach adopted for this study is presumed 
appropriate the author is aware of its inherent limits. For example, using computer 
software SPSS which generates quantitative data would add to the validity of the 
proposed concepts. The study is limited to five participants from the East Midlands 
region in the UK. Nonetheless, the output which is ‘knowledge and innovative capability 
development model’ illuminates the salient mechanisms and process that mitigate the 
knowledge supply-chain of small born-global bio-tech firms. 
Finally, the author makes two important recommendations. He recommends studies 
that test the extent to which independent variables such as: business, social networks, 
competence, goodwill trust, prior learning and absorptive capacity influence the 
innovative capability development process of small born-global bio-tech firms. The 
traditionally held view that large bio-pharmaceuticals are the most dominant force in 
global markets might well be evolving. The advent of small born-global bio-tech firms on 
the global stage in substantial numbers, worldwide, reflects an emerging business model 
with the potential to perhaps become the most dominant in the harsh economic times in 
which large organisations are feeling the strain. 
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In that regard, the born-global phenomenon requires great attention because it heralds 
the emergence of a new phase in international exchange systems whereby regardless of 
the size of a business, it can play an important role in global markets. From that 
perspective, he also recommends future studies that investigate how small born-global 
bio-tech firms learn to cope with the complexity of global markets given their cultural 
diverse nature. This will help us to deepen our understanding of how born-global firms 
organise the exchange of ideas, technologies, people and information in global networks. 
References 
Adner, R. (2006) ‘Match your innovation strategy to your innovation ecosystem’, Harvard 
Business Review, Vol. 84, No. 4, pp.98–107. 
Ahuja, G. (2000) ‘Collaboration networks, structural holes, and innovation: a longitudinal study’, 
Administrative Science Quarterly, Vol. 45, No. 3, pp.425–455. 
Andersen, O. (1993) ‘On the internationalisation process of firms: a critical analysis’, Journal of 
International Business Studies, Vol. 24, No. 2, pp.209–232. 
Asheim, B. and Gertler, M. (2005) ‘The geography of innovation’, in Fagerberg, J., Mowery, D. 
and Nelson, R. (Eds.): The Oxford Hand book of Innovation, pp.291–317, Oxford University 
Press, Oxford. 
Bachmann, R. and Inkpen, A.C. (2011) ‘Understanding institutional-based trust building processes 
in inter-organisational relationships’, Organisation Studies, Vol. 32, No. 2, pp.281–301. 
Basile, A. (2010) ‘Networking system and innovation outputs: the role of science and technology 
parks’, International Journal of Business and Management, Vol. 6, No. 5, pp.2–15. 
Baxter, P. and Susan, J. (2008) ‘Qualitative case-study methodology: study design and 
implementation for novice researchers’, The Qualitative Report, Vol. 13, No. 4, pp.544–559 
[online] http://www.nova.edu/ssss/QR/QR13-4/baxter.pdf (accessed 1 July 2012). 
Bellamy, C. and Perri, G. (2009) Principles of Research Design: A Guide to Methodology in Social 
Science, Sage Publications Inc., London. 
Bhowmick, S. (2004) ‘Towards understanding small firm internationalisation – technology based 
SME focus’, Frontiers of E-Business Research, pp.758–770, University of Auckland. 
Blomqvist, K. (1997) ‘The many faces of trust’, Scandinavian Journal of Management, Vol. 13, 
No. 3, pp.271–286. 
Booth, B.L. (2009) ‘Beyond the biotech IPO: a brave new world’, Nature Biotechnology, Vol. 27, 
No. 8, pp.702–709. 
Boschma, R. (2005) ‘Proximity and innovation: a critical assessment’, Regional Studies, Vol. 39, 
No. 1, pp.61–74. 
Bramwell, A., Hepburn, N. and Wolfe, D.A. (2012) ‘Growing innovation ecosystems:  
university-industry knowledge transfer and regional economic development in Canada’, Social 
Sciences and Humanities Research Council of Canada, pp.1–62. 
Breschi, S. and Malebra, F. (2005) Clusters, Networks and Innovation, Oxford University Press 
Inc., New York. 
Burns, P. (2012) Entrepreneurship and Small Business: Start-up and Growth, 3rd ed., Palgrave 
Macmillan, Basingstoke. 
Burt, R.S. (2002) ‘Structural holes and good ideas’, American Journal of Sociology, Vol. 110,  
No. 2, pp.349–399. 
Cohen, L., Manion, L. and Morrison, K. (2007) Research Methods in Education, 6th ed., 
Routledge, London. 
Cohen, W.M. and Levinthal, D.A. (1990) ‘Absorptive capacity: a new perspective on learning and 
innovation’, Administrative Science Quarterly, Special issue, Vol. 35, No. 1, pp.128–152. 
   
 
   
   
 
   
   
 
   
   54 A. Simba    
 
    
 
 
   
   
 
   
   
 
   
       
 
Cooke, P. (2001) ‘Regional innovation systems, clusters and the knowledge economy’, Industrial 
and Corporate Change, Vol. 10, No. 4, pp.945–974. 
Cooke, P. (2003) ‘The evolution of biotechnology in three continents: Schumpeterian or 
Penrosian’, European Planning Studies, Special Issue on Biotechnology Clusters and Beyond, 
October, Vol. 11, No. 7, pp.757–763. 
Crocker, G. (2010) Opportunity: UK Life Science Start-up Report 2010, Mobius Life Sciences 
Fund, Nottingham. 
Daud, S. and Yussof, W.F.W. (2010) ‘Knowledge management and firm performance in SMEs: the 
role of social capital as a mediating variable’, Asian Academy of Management Journal,  
Vol. 15, No. 2, pp.135–155. 
Davis, J.A. (1970) ‘Clustering and hierarchy in interpersonal relations: testing two graph theoretical 
models on 742 sociograms’, American Sociological Review, Vol. 35, No. 5, pp.843–852. 
Easterby-Smith, M., Thorpe, R. and Jackson, P. (2012) Management Research, 4th ed., Sage 
Publication, London. 
Eckstein, H. (1975) ‘Case study and theory in political science’, in Greenstein, F.I. and  
Polsby, N.W. (Eds.): Handbook of Political Science, Addison-Wesley, Reading, Mass. 
Eisenhardt, K. and Graebner, M. (2007) ‘Theory building from cases: opportunities and 
challenges’, Academy of Management Journal, Vol. 50, No. 1, pp.50–57. 
Elfring, T. and Hulsink, W. (2003) ‘Networks in entrepreneurship: the case of high-technology 
firms’, Small Business Economics, Vol. 21, No. 4, pp.409–422. 
Feldman, M., Feller, I., Bercovitz, J. and Burton, R. (2002) ‘Equity and the technology transfer 
strategies of American Research Universities’, Management Science, Vol. 48, No. 1,  
pp.105–121. 
Freeman, S., Hutchings, K., Lazaris, M. and Zyngier, S. (2010) ‘A model of rapid knowledge 
development: the smaller born-global firm’, International Business Review, Vol. 19, No. 1, 
pp.70–84. 
Fukuyama, F. (1995) Trust: The Social Virtues and the Creation of Prosperity, Hamish Hamilton, 
London. 
Gerring, J. (2001) Social Science Methodology: A Critical Framework, Cambridge University 
Press, NY [online] http://www.bu.edu/polisci/JGERRING/Causation%20(JTP).pdf (accessed 
23 September 2012). 
Gerring, J. (2005) ‘Causation: a unified framework for the social science’, Journal of Theoretical 
Politics, Vol. 17, No. 2, pp.163–198, Sage Publications. 
Gubbins, C. and MacCurtain, S. (2008) ‘Understanding the dynamics of collective learning: the 
role of trust and social capital’, Advances in Developing Human Resources, Vol. 10 [online] 
http://adh.sagepub.com/content/10/4/578 (accessed 10 August 2012). 
Hautamaki, A. (2007) Kestävä innovointi. Innovaatiopolitiikka uusien haasteiden edessä, Sitran 
raportteja 76. Sitr,. Helsinki. 
Helfat, C.E. and Peteraf, M.A. (2003) ‘The dynamic resource-based view: capability life cycles’, 
Strategic Management Journal, Vol. 24, No. 10, pp.997–1010. 
Hill, C.W.L. (1990) ‘Cooperation, opportunism, and the invisible hand: implications for transaction 
cost theory’, Academy of Management Review, Vol. 15, No. 3, pp.500–513. 
Hisrich, R.D. (2012) International Entrepreneurship: Starting and Developing and Managing a 
Global Venture, 2nd ed., Sage Publications, Thousand Oaks, CA. 
Ho, M.W.Y. and Wilson, M. (2006) ‘Knowledge resources for university spinouts: the role of the 
academic entrepreneur’, Academic of Management Proceedings, Auckland University of 
Technology, Auckland, New Zealand. 
Hoy, W.K. and Tschannen-Moran, M. (1999) ‘Five forces of trust: an empirical confirmation in 
urban elementary schools’, Journal of School Leadership, Vol. 9, No. 3, pp.184–208. 
Huberman, M.A. and Miles, M.B. (1994) The Qualitative Researcher’s Companion, Sage 
Thousand Oaks, NY. 
   
 
   
   
 
   
   
 
   
    A new model of knowledge and innovative capability development 55    
 
    
 
 
   
   
 
   
   
 
   
       
 
Hughes, T. and O’Regan, N. (2009) ‘The effectiveness of knowledge networks: an investigation of 
manufacturing SMEs’, Education +Training, Vol. 51, Nos. 8/9, pp.665–681. 
Hutchings, K. and Michailova, S. (2006) ‘Impacts of culture and institutions on knowledge sharing 
in Russia and China’, International Journal of Emerging Markets, Vol. 1, No. 1, pp.21–34. 
Inkpen, A.C. and Tsang, E. (2005) ‘Social capital, networks, and knowledge transfer’, Academy of 
Management Review, Vol. 30, No. 1, pp.146–165. 
Jansen, J.J.P., van den Bosch, F.A.J. and Volberda, H.W. (2005) ‘Managing potential and realised 
absorptive capacity: how do organisational antecedents matter?’, Academy of Management 
Journal, Vol. 48, No. 6, pp.999–1015. 
Johnson, J. and Vahlne, J-E. (1977) ‘The internationalisation process of the firm’, Journal of 
International Business Studies, Vol. 8, No. 1, pp.23–32. 
Johnson, J. and Vahlne, J-E. (2003) ‘Business relationship learning and commitment in the 
internationalisation process’, Journal of International Entrepreneurship, Vol. 1, No. 1,  
pp.83–101. 
Johnson, J. and Vahlne, J-E. (2009) ‘The Uppsala internationalisation process model revisited: 
from liability of foreignness to liability of outsidership’, Journal of International Business 
Studies, Vol. 40, No. 9, pp.1411–1431. 
Kang, K-N. and Park, H. (2012) ‘Influence of government R&D support and inter-firm 
collaborations on innovation in Korean biotechnology SMEs’, Technovation, January, Vol. 32, 
No. 1, pp.68–78 [online] http://www.elsevier.com/locate/technovation (accessed 13 July 
2012). 
Karra, N., Phillips, N. and Tracey, P. (2008) ‘Building the born-global firm developing 
entrepreneurial capabilities for international new venture success’, Long Range Planning,  
Vol. 41, No. 4, pp.440–458 [online] http://www.elsevier.com/locate/lrp (accessed 22 
December 2012). 
Knight, G.A. (2001) ‘Entrepreneurship and strategy in the international SME’, Journal of 
International Management, Vol. 7, No. 3, p.155–171. 
Knight, G.A. and Cavusgil, T.S. (1996) ‘The born global firm: a challenge to traditional 
internationalization theory’, in Cavusgil, S.T. and Madsen, T.K. (Eds.): Export 
Internationalizing Research – Enrichment and Challenges, Advances in International 
Marketing, Vol. 8, pp.11–26, JAI Press, New York, NY. 
Laine, K., Vander Sijde, P., Lahdeniemi, M. and Tarkkanen, J. (2008) ‘Higher education 
institutions and innovation in the knowledge society’, The Rectors’ Conference of Finnish 
University of Applied Science, ARENE. 
Lasserre, P. (2012) Global Strategic Management, 3rd ed., Palgrave MacMillan, NY. 
Lichtenthaler, U. and Lichtenthaler, E. (2009) ‘A capability-based framework for open innovation: 
complementing absorptive capacity’, Journal of Management Studies, Vol. 46, No. 8, p.8. 
Martin, R. and Sunley, P. (2011) ‘Regional competitiveness: clusters or dynamic comparative 
advantage’, in Huggins, R. and Izushi, H. (Eds.): Competition, Competitive Advantage, and 
Clusters: The Ideas of Michael Porter, pp.211–238, in press, Oxford University Press, Oxford, 
GB. 
Maxwell, A.L. and Levesque, M. (2011) ‘Trustworthiness: a critical ingredient for  
entrepreneurs seeking investors’, Entrepreneurship Theory and Practice,  
DOI: 10.1111/j.1540-6520.2011.00475.x. 
Miller, S.I. (1983) ‘Some comments on the logic of triangulation’, International Journal of 
Experimental Research in Education, Vol. 20, No. 2, pp.200–212. 
Mishra, A.K. (1996) ‘Organizational responses to crisis: the centrality of trust’, in Kramer, R.M. 
and Tyler, T.R. (Eds.): Trust in Organizations: Frontiers of Theory and Research,  
pp.261–287, Sage, Thousand Oaks, CA. 
Munos, B.H. (2009) ‘Lessons from 60 years of pharmaceutical innovation’, Reviews Drug 
Discovery, December, Vol. 8, pp.959–968, doi:10.1038/nrd2961. 
   
 
   
   
 
   
   
 
   
   56 A. Simba    
 
    
 
 
   
   
 
   
   
 
   
       
 
Nahapiet, J. and Ghoshal, S. (1998) ‘Social capital, intellectual capital, and the organisational 
advantage’, Academy of Management Review, Vol. 23, No. 2, pp.242–266. 
Newfield, N.A., Kuehl, B.P., Joanning, H. and Quinn, W.H. (1991) ‘We can tell you about psychos 
and shrinks: an ethnography of the family therapy of adolescent substance abuse’, in  
Todd, T.C. and Selekman, M.D. (Eds.): Family Therapy Approaches with Adolescent 
Substance Abusers, pp.277–310, Allyn and Bacon, Boston. 
Nonaka, I. and Takeuchi, H. (1995) The Knowledge-Creating Company, Oxford University Press, 
New York. 
Nonaka, I., Toyama, R. and Konno, N. (2000) ‘SECI, ‘Ba’ and leadership: a unified model of 
dynamic knowledge creation’, Long Range Planning, Vol. 33, No. 1, pp.5–34. 
Oviatt, B.M. and McDougall, P.P. (1994) ‘Towards a theory of international new venture’, Journal 
of International Business Studies, Vol. 25, No. 1, pp.45–64. 
Oviatt, B.M. and McDougall, P.P. (2005) ‘Defining international entrepreneurship and modelling 
the speed of internationalisation’, Entrepreneurship Theory and Practice, Vol. 29, No. 5, 
pp.537–553. 
Owen-Smith, J. and Powell, W.W. (2004) ‘Knowledge networks as channels and conduits: the 
effects of spillovers in the boston biotechnology community’, Organisation Science Journal, 
Vol. 15, No. 1, pp.5–21. 
Pittaway, L. (2000) The Social Construction of Entrepreneurial Behaviour, Thesis, Newcastle 
University Library. 
Porter, K., Whittinghton, K.B. and Powell, W.W. (2005) ‘The Institutional embeddedness of  
high-tech regions: relational foundations of the Boston biotechnology community: chapter 10 
in Breschi and Malerba, Clusters, Networks and Innovation, p.261. 
Powell, W. and Grodal, S. (2005) ‘Networks of innovators’, in Fagerberg, J., Mowery, D. and 
Nelson, R. (Eds.): The Oxford Handbook of Innovation, p.56, Oxford University Press, 
Oxford. 
Powell, W.W., Koput, K.W. and Smith-Doerr, L. (1996) ‘Inter-organisational collaboration and the 
locus of innovation: networks of learning in biotechnology’, Administrative Science Quarterly, 
Vol. 41, No. 1, pp.116–145. 
Pretty, J. and Ward, H. (2001) ‘Social capital and the environment’, World Development, Vol. 29, 
No. 2, pp.209–227. 
Putnam, R.D. (1993) ‘The prosperous community: social capital and public life’, The American 
Prospect, Vol. 13, No. 1, pp.35–42. 
Rafols, I., Hopkins, M.M., Hoekman, J., Siepel, J., O’Hare, A., Perianes-Rodriguez, A. and 
Nightingale, P. (2012) ‘Big pharma, little science? A bibliometric perspective on big  
pharma’s R&D decline’, Technological Forecasting & Social Change, pp.1–17,  
DOI: 10.1016/j.techfore.2012.06.007, SciVerse [online] http://www.ScienceDirect.com 
(accessed 7 August 2012). 
Ridder, H., Hoon, C. and McCandless, A. (2009) ‘The theoretical contribution of case study 
research to the field of strategy and management’, in, Bergh, D.D. and Ketchen, D.J. (Eds.): 
Research Methodology in Strategy and Management, Vol. 5, pp.137–175, Elsevier, Oxford. 
Rogers, E.M. (1962) Diffusion of Innovation, The Free Press, New York, NY. 
Sartori, G. (1970) ‘Concept misinformation in comparative politics’, American Political Science 
Review, Vol. 64, No. 4, pp.1033–1053. 
Saunders, M., Lewis, P. and Thornhill, A. (2007) Research Methods for Business Students, 4th ed., 
Prentice Hall, Essex, London. 
Schilling, M.A. (2008) Strategic Management of Technological Innovation, 2nd ed., McGraw-Hill 
Companies, New York, NY. 
Schumpeter, J.A. (1950) History of Economic Analysis, Allen and Anwin, London. 
   
 
   
   
 
   
   
 
   
    A new model of knowledge and innovative capability development 57    
 
    
 
 
   
   
 
   
   
 
   
       
 
Şegun, A.F. and Önder, C. (2011) ‘The conditional impact of competence trust on inter-firm 
learning in a collectivist SME context’, Industry and Innovation, Vol. 18, No. 8, pp.791–812. 
Available at: http://dx.doi.org/10.1080/13662716.2011.621746 
Sengun, A.E. (2009) ‘Which type of trust for inter-firm learning? Paper to be presented at the 
Summer Conference 2009, DRUID, Copenhagen Business School, Denmark. 
Siggelkow, N. (2007) ‘Persuasion with case-study’, Academy of Management Journal, Vol. 50,  
No. 1, pp.20–24. 
Simba, A. (2012) Investigating How Small Born-global Biotech Firms in the East Midlands, UK 
Develop their Innovative Capabilities: A Multi-case Approach, Doctoral thesis, Nottingham 
Trent University Library. 
Sitkin, S.B. and Pablo, A.L. (1992) ‘Reconceptualising the determinants of risk behaviour’, 
Academy of Management Review, Vol. 17, No. 1, pp.9–38. 
Stake, R. (1995) The Art of Case-study Research, Sage Publications, Thousand Oaks, CA. 
Stuart, T.E., Ozdemir, S.Z. and Ding, W.W. (2007) ‘Vertical alliance networks: The case  
of university-biotechnology-pharmaceutical alliance chains’, Research Policy, Vol. 36, 
pp.477–498. 
Subramanian, A.M. and Soh, P-H. (2010) ‘An empirical examination of the science–technology 
relationship in the biotechnology industry’, Journal of Engineering and Technology 
Management, Vol. 27, No. 3, pp.160–171. 
Swain, C. (2012) Big Pharma in Crisis?, Business Management, Cambridge MedChem Consulting, 
[online] http://www.samedanltd.com (accessed 28 November 2012). 
Sydow, J. (1998) ‘Understanding the constitution of interorganisational trust in trust within and 
between organisations’, in Lane, C. and Bachman, R. (Eds.): Conceptual Issues and Empirical 
Applications, Oxford University Press. 
Taylor, S.J. and Bogdan, R. (1984) Introduction to Qualitative Research Methods: The Search for 
Meanings, John Wiley & Sons, New York. 
Teece, D., Pisano, G. and Shuen, A. (1997) ‘Dynamic capabilities and strategic management’, 
Strategic Management Journal, Vol. 18, No. 7, pp.509–533. 
Todtling, F., Lehner, P. and Kaufmann, A. (2009) ‘Do different types of innovation rely on  
specific kinds of knowledge interactions?’, Technovation, Vol. 29, No. 1, pp.59–71 [online] 
http://www.elsevier.com/locate/technovation (accessed 15 September 2012). 
Tsai, W. and Ghoshal, S. (1998) ‘Social capital and value creation: the role of intra-firm networks’, 
Academy of Management Journal, Vol. 41, No. 4, pp.464–476. 
Turnbull, P.W. (1987) ‘A challenge to the stages theory of the internationalisation process’, in 
Reid, S.D. and Rosson, P.J. (Eds.): Managing Export Entry and Expansion, Praeger,  
New York. 
Wall, R.S. (2009) NETSCAPE: Cities and Global Corporate Networks, Erasmus Research Institute 
of Management (ERIM), Doctoral thesis, Erasmus Universiteit Rotterdam. 
Welter, F. (2012) ‘All you need is trust? A critical review of the trust and entrepreneurship 
literature’, International Small Business Journal, Vol. 30, No. 3, pp.193–212. 
Whitner, E.M., Brodt, S.E., Korsgaard, M.A. and Werner, J.M. (1998) ‘Managers as initiator of 
trust: an exchange relationship framework for understanding managerial trustworthy 
behaviour’, Academy of Management Review, Vol. 23, No. 3, pp.513–530. 
William, J.L. (1992) ‘Don’t discuss it: reconciling illness, dying, and death in a medical school 
anatomy laboratory’, Family Systems Medicine, Vol. 10, No. 1, pp.65–78. 
Wolfe, D., Bramwell, A. and Munro, A. (2011) ‘Clusters, collaboration and networking: review of 
international best practice and implications for innovation in Canada’, Final report prepared 
for the Strategy and Development Branch, National Research Council, PROGRIS, Munk 
School of Global Affairs, Toronto. 
 
   
 
   
   
 
   
   
 
   
   58 A. Simba    
 
    
 
 
   
   
 
   
   
 
   
       
 
Yin, R.K. (2003) Case-study Research: Design and Methods, 3rd ed., Sage Publications, Thousand 
Oaks, CA. 
Yin, R.K. (2009) Case-study Research: Design and Methods, 4th ed., Sage Publications, Thousand 
Oaks, CA. 
Zucker, L., Darby, M. and Amstrong, J. (1998) ‘Geographically localised knowledge: spillovers or 
markets?’, Economics Enquiry, Vol. 36, No. 1, pp.65–86. 
